nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2016 | Original Article

Multimodal imaging based on MRI and PET reveals [¹⁸F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma

verfasst von: Aurélien Corroyer-Dulmont, Elodie A. Pérès, Aurélie N. Gérault, Ariel Savina, Fanny Bouquet, Didier Divoux, Jérôme Toutain, Méziane Ibazizène, Eric T. MacKenzie, Louisa Barré, Myriam Bernaudin, Edwige Petit, Samuel Valable

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The primary objective of this study was to compare the ability of PET and MRI biomarkers to predict treatment efficacy in a preclinical model of recurrent glioblastoma multiforme.

Methods

MRI (anatomical, diffusion, vasculature and oxygenation) and PET ([¹⁸F]FDG and [¹⁸F]FLT) parameters were obtained 3 days after the end of treatment and compared with late tumour growth and survival.

Results

Early after tumour recurrence, no effect of treatment with temozolomide combined with bevacizumab was observed on tumour volume as assessed by T2-W MRI. At later times, the treatment decreased tumour volume and increased survival. Interestingly, at the earlier time, temozolomide + bevacizumab decreased [¹⁸F]FLT uptake, cerebral blood volume and oedema. [¹⁸F]FLT uptake, oedema and cerebral blood volume were correlated with overall survival but [¹⁸F]FLT uptake had the highest specificity and sensitivity for the early prediction of treatment efficacy.

Conclusion

The present investigation in a preclinical model of glioblastoma recurrence underscores the importance of multimodal imaging in the assessment of oedema, tumour vascular status and cell proliferation. Finally, [¹⁸F]FLT holds the greatest promise for the early assessment of treatment efficacy. These findings may translate clinically in that individualized treatment for recurrent glioma could be prescribed for patients selected after PET/MRI examinations.

Nur mit Berechtigung zugänglich

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed

Desjardins A, Friedman HS. Neuro-oncology: glioblastoma – community adjusts to new standard of care. Nat Rev Neurol. 2012;8:244–6.CrossRefPubMed

Eftimov N, Ivanov ID, Petkov AP, Nakov E. Management of recurrent high-grade gliomas. Cancer Ther. 2007;5:243–52.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943–53.CrossRefPubMed

Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455–68.CrossRefPubMed

Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76:87–93.PubMedCentralCrossRefPubMed

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.CrossRefPubMed

Van Linde ME, Verhoeff JJ, Richel DJ, van Furth WR, Reijneveld JC, Verheul HM, et al. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. Oncologist. 2015;20:107–8.

Corroyer-Dulmont A, Pérès EA, Petit E, Guillamo J-S, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol. 2013;15:41–56.PubMedCentralCrossRefPubMed

10.

Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32:882–9.CrossRefPubMed

11.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3′-Deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29–36.PubMedCentralCrossRefPubMed

12.

Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, et al. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One. 2013;8, e67911.PubMedCentralCrossRefPubMed

13.

Lemasson B, Christen T, Serduc R, Maisin C, Bouchet A, Le Duc G, et al. Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model. Radiology. 2012;265:743–52.CrossRefPubMed

14.

Jordan BF, Magat J, Colliez F, Ozel E, Fruytier AC, Marchand V, et al. Mapping of oxygen by imaging lipids relaxation enhancement: a potential sensitive endogenous MRI contrast to map variations in tissue oxygenation. Magn Reson Med. 2013;70:732–44.CrossRefPubMed

15.

Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJH, et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013;19:1178–83.PubMedCentralCrossRefPubMed

16.

Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049–55.CrossRefPubMed

17.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856–64.CrossRefPubMed

18.

Derlon JM, Chapon F, Noël MH, Khouri S, Benali K, Petit-Taboué MC, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778–87.CrossRefPubMed

19.

Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.CrossRefPubMed

20.

Corroyer-Dulmont A, Pérès EA, Petit E, Durand L, Marteau L, Toutain J, et al. Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma. Biol Chem. 2013;394:529–39.CrossRefPubMed

21.

Valable S, Eddi D, Constans J-M, Guillamo J-S, Bernaudin M, Roussel S, et al. MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model. Neuro Oncol. 2009;11:488–502.PubMedCentralCrossRefPubMed

22.

Varallyay C, Muldoon L, Gahramanov S. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29:853–60.PubMedCentralCrossRefPubMed

23.

Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38:781–93.PubMed

24.

Lemasson B, Valable S, Farion R, Krainik A, Rémy C, Barbier EL. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. 2013;69:1–3.CrossRef

25.

Hawkins-Daarud A, Rockne RC, Anderson AR, Swanson KR. Modeling tumor-associated edema in gliomas during anti-angiogenic therapy and its impact on imageable tumor. Front Oncol. 2013;3:66.PubMedCentralCrossRefPubMed

26.

Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012;106:111–9.CrossRefPubMed

27.

Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther. 2013;13:1319–25.CrossRefPubMed

28.

Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.CrossRefPubMed

29.

Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 2009;11:301–10.PubMedCentralCrossRefPubMed

30.

McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;76:1537–45.PubMedCentralCrossRefPubMed

31.

Pérès EA, Gérault AN, Valable S, Roussel S. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. Oncotarget. 2015;6:2101–19.PubMedCentralCrossRefPubMed

32.

Zhao F, Cui Y, Li M, Fu Z, Chen Z, Kong L, et al. Prognostic value of 3′-Deoxy-3′-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas. Nucl Med Biol. 2014;41:710–5.

33.

Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM. First use of 18F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav. 2014;4:312–5.PubMedCentralCrossRefPubMed

34.

Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. 18F-FLT and 18F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014;41:1199–209.PubMedCentralCrossRefPubMed

35.

Jeong SY, Lim SM. Comparison of 3′-deoxy-3′-[(18)F]fluorothymidine PET and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol. 2012;39:977–81.CrossRefPubMed

36.

Seung JC, Jae SK, Jeong HK, Seung JO, Jeong GL, Chang JK, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–9.CrossRef

37.

Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE. 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006;8:340–7.CrossRefPubMed

38.

Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009;24:879–91.PubMed

39.

Godoy PR, Mello SS, Magalhães DA, Donaires FS, Nicolucci P, Donadi EA, et al. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res. 2013;756:46–55.CrossRefPubMed

Titel: Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
verfasst von: Aurélien Corroyer-Dulmont
Elodie A. Pérès
Aurélie N. Gérault
Ariel Savina
Fanny Bouquet
Didier Divoux
Jérôme Toutain
Méziane Ibazizène
Eric T. MacKenzie
Louisa Barré
Myriam Bernaudin
Edwige Petit
Samuel Valable
Publikationsdatum: 01.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3225-0

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels

2015 Young Investigators Meeting

Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment

Symptomatic versus asymptomatic knees after bilateral total knee arthroplasty: what is the difference in SPECT/CT?

18F-FDG PET in small-cell cervical cancer: a prospective study with long-term follow-up

Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome